Last reviewed · How we verify
Pegintron + Riba
Pegintron (pegylated interferon alfa-2b) and ribavirin work together to inhibit hepatitis C virus replication by enhancing innate immune responses and directly blocking viral RNA synthesis.
Pegintron (pegylated interferon alfa-2b) and ribavirin work together to inhibit hepatitis C virus replication by enhancing innate immune responses and directly blocking viral RNA synthesis. Used for Chronic hepatitis C virus infection (genotype-dependent), Hepatitis C with compensated cirrhosis.
At a glance
| Generic name | Pegintron + Riba |
|---|---|
| Sponsor | Chang Gung Memorial Hospital |
| Drug class | Antiviral combination therapy (interferon + nucleoside analog) |
| Target | Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Pegintron is a long-acting interferon that activates antiviral immune responses and inhibits viral protein synthesis. Ribavirin is a nucleoside analog that directly interferes with HCV RNA replication and may enhance immune responses. Together, they form the backbone of direct-acting antiviral regimens for chronic hepatitis C infection.
Approved indications
- Chronic hepatitis C virus infection (genotype-dependent)
- Hepatitis C with compensated cirrhosis
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hemolytic anemia
- Thrombocytopenia
- Depression/mood changes
- Headache
- Nausea
- Neutropenia
Key clinical trials
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients (PHASE3)
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (PHASE1)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy (PHASE3)
- Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C (PHASE3)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy (PHASE3)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients (PHASE3)
- HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin (PHASE3)
- Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegintron + Riba CI brief — competitive landscape report
- Pegintron + Riba updates RSS · CI watch RSS
- Chang Gung Memorial Hospital portfolio CI